Dogwood Therapeutics filings document the regulatory record of a Delaware development-stage biopharmaceutical company focused on pain and neuropathy medicines. Its 8-K reports include financial results, Regulation FD shareholder letters, corporate updates, and material-event disclosures tied to the Halneuron® and SP16 IV development programs.
Proxy and meeting filings cover stockholder voting matters, governance, executive compensation, equity incentive plans, and Nasdaq-related approvals for warrant exercises and common stock issuances. The filing record also documents capital-structure matters, securities purchase agreements, equity awards, and risk-oriented disclosures associated with a clinical-stage biotechnology issuer.
Dogwood Therapeutics, Inc. is presenting a preliminary proxy for a Special Meeting to approve several Nasdaq-related matters tied to newly issued preferred stock and equity plan changes. The filing notes that a 1.7 inhibitor has received FDA fast-track designation for chemotherapy-induced neuropathic pain, and states that an increase in capitalization backed by experienced investors will support research, partnerships and business development. The company issued 211,951 shares in connection with a Share Exchange Agreement and 382,034 shares under an Exclusive License Agreement; those shares are not entitled to vote on related proposals under Nasdaq rules. The Proposals seek shareholder approval for potential conversion issuances of Series A, A-1 and A-2 Non-Voting Convertible Preferred Stock, adoption of a revised 2020 Equity Incentive Plan, and authority to adjourn if additional proxy solicitation or Nasdaq approval is needed. The filing describes conversion mechanics, cash settlement rights for undelivered shares, voting limitations for street-held shares, abstention consequences (notably for Proposal No. 3) and timing windows for director nominations.
Dogwood Therapeutics, Inc. has filed a shelf registration on Form S-3 to register resale of shares under a prospectus that covers Common Stock and multiple series of Preferred Stock. The prospectus states 43,000,000 shares of Common Stock and 2,000,000 shares of preferred stock authorized, including specific Series allocations for Series A, A-1 and A-2. The document identifies named selling stockholders and discloses that percentages are based on 2,293,162 shares of Common Stock outstanding as of September 30, 2025. The prospectus incorporates recent SEC filings by reference, including the 2024 Form 10-K and multiple 10-Qs and 8-Ks filed in 2025, and includes customary undertakings regarding post-effective amendments, prospectus use and liability. The registration statement lists exhibits such as Certificates of Designation for the preferred series, legal opinions, accountant consents and powers of attorney and is signed by the CEO, CFO and members of the board.
Dogwood Therapeutics entered into an Exclusive Licensing Agreement with Serpin Pharma and Rejuvenation Labs granting Dogwood a royalty-free, sublicensable global license to develop Serpin's intravenous formulation of SP16, a first-in-class LRP1 agonist with reported anti-inflammatory and neural repair activity that may treat chemotherapy-induced peripheral neuropathy. As consideration, Dogwood agreed to issue 191,017 shares of common stock and 89.5939 shares of Series A-2 Non-Voting Convertible Preferred Stock to Serpin Pharma and the same amounts to Rejuvenation Labs. Tungsten received 10.8694 shares of Series A-2 Preferred Stock as advisor compensation. Related registration, support and voting agreements require Serpin, Tungsten-affiliated holders, and Sealbond to vote their shares in favor of proposals concerning potential issuances related to Series A, Series A-1 and Series A-2 conversions, certain equity plan matters, and possible adjournment of the meeting.